(Q45875605)

17 December 2017

title

Fifteen years of population based experience in Finland with a plasma-derived monoclonal purified factor VIII concentrate (English)

1 reference

17 December 2017

0 references

A Mäkipernaa

1

1 reference

17 December 2017

L von Bonsdorff

series ordinal

2

1 reference

17 December 2017

publication date

25 February 2008

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

14

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

612-614

1 reference

17 December 2017

Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01674.X

Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01674.X

Viral markers and use of factor products among Finnish patients with bleeding disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01674.X

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01674.X

10.1111/J.1365-2516.2008.01674.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

release_e5y5h4tlzbfxznt2ipt3hn2rey

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e5y5h4tlzbfxznt2ipt3hn2rey

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

17 December 2017